ArticleGastroenterology research and practice2026
Gui-Shao San Umbilical Moxibustion for Diarrhea-Predominant Irritable Bowel Syndrome With Liver Depression and Spleen Deficiency Pattern: A Randomized Controlled Trial.
Article in Gastroenterology research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gui-Shao San Umbilical Moxibustion for Diarrhea-Predominant Irritable Bowel Syndrome With Liver Depression and Spleen Deficiency Pattern: A Randomized Controlled Trial.Gastroenterology research and practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This randomized controlled trial aimed to evaluate the effects of Gui-Shao San umbilical moxibustion on symptoms of the disease, psychological well-being, and quality of life in patients with IBS-D. Interventions: The patients were randomly assigned to three groups: One received Gui-Shao San umbilical moxibustion alongside conventional Western medicine treatment; one received placebo umbilical moxibustion alongside conventional Western medicine treatment; and one received only conventional Western medicine treatment for use as a positive control group. Outcomes: The primary outcome measures included TCM clinical symptom score, IBS-SSS, and grading criteria for TCM syndrome scores. Secondary outcome measures included SAS, SDS, and IBS-QOL. The effects of the intervention on these outcomes were measured at three time points: baseline (T0), Week 2 (T1), and Week 4 (T2). At Week 8, the recurrence of patients was measured based on whether their IBS-SSS score increased by one grade. Results: After 4 weeks of treatment, compared with the positive drug control group, both the Gui-Shao San umbilical moxibustion group and the placebo umbilical moxibustion group effectively relieved patients' symptoms, anxiety, and depression, while improving their quality of life. Significant differences were observed between groups in IBS-SSS scores (120.61 ± 30.61 vs. 128.13 ± 41.85 vs. 161.82 ± 59.87, Conclusions: Gui-Shao San umbilical moxibustion is an effective method for treating IBS-D. Further rigorous, large-scale, long-term trials are needed to evaluate the therapeutic effects of Gui-Shao San umbilical moxibustion, focusing on interdisciplinary collaboration. Trial Registration: The International Traditional Medicine Clinical Trial Registry (ITMCTR) Reg. No.: ITMCTR2025001072.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.